Study Uncovers New Immune Pathways in mRNA Vaccine-Driven Tumor Destruction
Updated
Updated · Newswise · Apr 17
Study Uncovers New Immune Pathways in mRNA Vaccine-Driven Tumor Destruction
7 articles · Updated · Newswise · Apr 17
A new study reveals mRNA vaccines can trigger strong anti-tumor immune responses through unconventional pathways, even without classical type 1 dendritic cells.
Researchers found that both cDC1 and cDC2 dendritic cell subtypes can independently prime CD8+ T cells, enabling effective tumor clearance in mice.
These findings could guide the design of more effective mRNA cancer vaccines and help explain differences in patient responses to immunotherapy.
After recent trial failures, can this new immune discovery actually deliver a cancer cure?
Can artificial intelligence succeed in designing cancer vaccines where humans have struggled?
How can we stop viral misinformation from killing the promise of mRNA cancer vaccines?
With a $100,000 price tag, will personalized cancer vaccines only be for the wealthy?
BioNTech's founders are leaving. Is it a retreat or a new attack plan against cancer?
mRNA Vaccines Double Survival in Advanced Cancer by Activating cDC2 and Resetting Immune Response
Overview
Recent studies reveal that mRNA-LNP vaccines activate the immune system mainly through cDC2 cells using a unique cross-dressing mechanism, allowing strong CD8 T cell responses even without cDC1 cells. This leads to distinct T cell profiles and a different immune response compared to natural infections. Clinically, administering COVID-19 mRNA vaccines alongside immune checkpoint inhibitors (ICIs) significantly improves survival in lung cancer and melanoma patients by triggering a type-I interferon surge that primes T cells, while ICIs block tumor defenses. At the molecular level, lipid nanoparticles cause inflammation in stromal cells, acting as an adjuvant, while mRNA induces interferon responses in dendritic cells, together providing a blueprint for designing more effective vaccines.